Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A092205
Study Title: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
CTO #: 104240
NCT Number: NCT06589804
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Larynx; Lip, Oral Cavity and Pharynx
Study Objectives: To assess whether the combination of cetuximab and pembrolizumab (Arm 2) compared to pembrolizumab alone (Arm 1) results in improved overall survival (OS) in subjects with platinum refractory HNSCC.